Investor Presentaiton

FY 23 : Overall growth of 2% in a challenging year GIF-10% اشا ~10% cc growth for Formulations. Business restructuring in Europe Emerging Markets delivered robust growth of 16% cc, driving overall Formulations J Sequent Proven Ability In Life Sciences Subdued sales of APIs Mahad site awarded the EcoVadis Sustainability Silver Medal Ni JAPI API: Focus on Top 10 AH customers. Regulated markets contribute to 72% of sales § ALIVIRA New comprehensive cost reduction and process efficiency improvement program APIS - Accelerating new product pipeline : 8 new filings (5 USVMF + 3 CEPS 4

View entire presentation